Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis.

Wu C, Chen X, Liu J, Li MY, Zhang ZQ, Wang ZQ.

Helicobacter. 2011 Apr;16(2):131-8. doi: 10.1111/j.1523-5378.2011.00826.x.

PMID:
21435091
2.

Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.

Li Y, Huang X, Yao L, Shi R, Zhang G.

Wien Klin Wochenschr. 2010 Jul;122(13-14):413-22. doi: 10.1007/s00508-010-1404-3. Epub 2010 Jul 16.

PMID:
20628905
3.

Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.

Bago J, Pevec B, Tomić M, Marusić M, Bakula V, Bago P.

Wien Klin Wochenschr. 2009;121(1-2):47-52. doi: 10.1007/s00508-008-1122-2.

PMID:
19263014
4.
5.

[Efficacy of second-line treatment based on moxifloxacin triple therapy for Helicobacter pylori infection].

Zheng XL, Xu L.

Zhonghua Yi Xue Za Zhi. 2010 Jan 12;90(2):83-6. Chinese.

PMID:
20356487
6.

[Trial of moxifloxacin-containing triple therapy after initial and second-line treatment failures for Helicobacter pylori infection].

Cheon JH, Kim N, Lee DH, Kim JW, Hwang JH, Park YS, Kim JM, Suh SO, Jung HC, Song IS.

Korean J Gastroenterol. 2005 Feb;45(2):111-7. Korean.

7.
8.

Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.

Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD.

Am J Gastroenterol. 2010 Jan;105(1):65-73. doi: 10.1038/ajg.2009.508. Epub 2009 Sep 15. Review.

PMID:
19755966
9.

[Efficacy of moxifloxacin-based triple therapy to eradicate Helicobacter pylori infection].

Wang CD, Zhuang ZH, Lu D, Li WQ, Wu T, Chen YL.

Zhonghua Yi Xue Za Zhi. 2010 Jan 12;90(2):87-91. Chinese.

PMID:
20356488
10.

Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.

Fischbach LA, van Zanten S, Dickason J.

Aliment Pharmacol Ther. 2004 Nov 15;20(10):1071-82.

11.

Moxifloxacin-tetracycline-lansoprazole triple therapy for first-line treatment of Helicobacter pylori infection: a prospective study.

Taş A, Akbal E, Koçak E, Köklü S.

Helicobacter. 2011 Feb;16(1):52-4. doi: 10.1111/j.1523-5378.2010.00817.x.

PMID:
21241413
12.

Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H. pylori: A prospective study.

Ergül B, Koçak E, Taş A, Filik L, Köklü S.

Clin Res Hepatol Gastroenterol. 2013 Nov;37(5):527-9. doi: 10.1016/j.clinre.2012.10.014. Epub 2013 Jan 9. No abstract available.

PMID:
23312494
13.

Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer.

Nie Y, Li Y, Wu H, Sha W, Du H, Dai S, Wang H, Li Q.

Helicobacter. 1999 Jun;4(2):128-34.

PMID:
10382127
14.

Nitrofuran-based regimens for the eradication of Helicobacter pylori infection.

Buzás GM, Józan J.

J Gastroenterol Hepatol. 2007 Oct;22(10):1571-81. Review.

PMID:
17845685
15.

High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial.

Bago P, Vcev A, Tomic M, Rozankovic M, Marusić M, Bago J.

Wien Klin Wochenschr. 2007;119(11-12):372-8.

PMID:
17634896
16.

Treatment of Helicobacter pylori infection: a review of the world literature.

van der Hulst RW, Keller JJ, Rauws EA, Tytgat GN.

Helicobacter. 1996 Mar;1(1):6-19. Review.

PMID:
9398908
17.

High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.

Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, Lu H.

Helicobacter. 2010 Jun;15(3):233-8. doi: 10.1111/j.1523-5378.2010.00758.x.

PMID:
20557366
18.

Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.

Köksal AS, Parlak E, Filik L, Yolcu OF, Odemiş B, Ulker A, Saşmaz N, Ozden A, Sahin B.

J Gastroenterol Hepatol. 2005 Apr;20(4):637-42.

PMID:
15836716
19.

Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.

Gené E, Calvet X, Azagra R, Gisbert JP.

Aliment Pharmacol Ther. 2003 May 1;17(9):1137-43.

20.

Antimicrobial resistance of H. pylori to the outcome of 10-days vs. 7-days Moxifloxacin based therapy for the eradication: a randomized controlled trial.

Bago J, Majstorović K, Belosić-Halle Z, Kućisec N, Bakula V, Tomić M, Bago P, Troskot R.

Ann Clin Microbiol Antimicrob. 2010 Apr 15;9:13. doi: 10.1186/1476-0711-9-13.

Items per page

Supplemental Content

Write to the Help Desk